Healthcare’s long-standing debate between volume and value is over. Payers made the call. CMS made it structural. What remains is an execution problem, and digital health technologies are the tools providers either master or fall behind on.

The CMS ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) Model, a 10-year voluntary payment program launching July 1, ties Medicare Part B reimbursement to measurable patient health improvements, not documented service hours. That is a fundamental shift. It means technology that tracks activity but does not generate defensible outcome data stops being an asset and starts being overhead.

Also read: The Biggest Innovations Happening in Medical Technology Devices Right Now

What Happens When Payment Follows Proof?

Thirty percent of US healthcare organizations now report at least a quarter of their revenue tied to value-based care arrangements, and over 60% expect higher VBC revenue this year compared to last. That growth follows a maturation in what digital health technologies can actually deliver. Remote patient monitoring, predictive EHR analytics, and interoperable data pipelines have moved from pilot projects into reimbursable, billable workflows with defined CPT codes and documentation requirements.

The reimbursement structure is explicit: providers get paid for device setup, data transmission, and clinical time spent reviewing and acting on that data. If monitoring information is not being used to adjust care plans, escalate risk, or generate meaningful patient interaction, the clinical and financial case for the technology collapses.

This is not a technical benchmark. It is a clinical accountability benchmark. The tools only earn their place inside a VBC arrangement when the data they produce changes a decision.

Why Is Interoperability the Make-or-Break Factor?

None of it works without clean data movement. NCQA’s retirement of the HEDIS Hybrid Method means healthcare organizations can no longer rely on manual chart review and must instead adopt FHIR-based data exchange and automated access to clinical data. That policy shift accelerates what was already a technical inevitability: FHIR-native architectures enable organizations to build data fabrics that reconcile conflicting records, validate information as it flows, and give clinicians reliable, real-time data they can act on.

For ACOs and risk-bearing organizations, this matters at a contract level. Connected data systems are essential to removing the uncertainty that stalls innovation. Fragmented records do not just create friction; in a VBC model, they create liability.

Can Predictive Analytics Actually Prevent Avoidable Utilization?

Approximately 65% of US hospitals now use AI-assisted predictive tools embedded in their EHR systems, with deployments advancing fastest in prior authorization processing, scheduling optimization, and ambient clinical documentation that synthesizes patient encounters into organized notes in real time.

In chronic care management, where readmission rates and care gaps directly affect shared savings calculations, predictive layering inside EHR workflows is the difference between catching a deteriorating patient at Monday’s alert and seeing them in the ED on Thursday. Clean, structured, semantically consistent clinical data is what makes those models work. Technology that clinicians do not adopt does not improve care, and digital health technologies designed without workflow integration have a consistent failure mode: high enrollment, low engagement, no demonstrable outcome shift.

Are Digital Therapeutics Becoming a Reimbursable Standard?

On the pharma and payer side, digital therapeutics are entering the VBC equation as clinical interventions, not supplementary features. FDA-cleared CBT apps, VR-based chronic pain management, and digital engagement tools are being evaluated against the same outcome accountability that governs every other VBC instrument.

The ACCESS model reinforces this direction explicitly. Its approximately 150 participating organizations include digitally enabled care delivery companies such as Headspace Health, Noom, and Teladoc Health, a deliberate CMS decision to bring technology-forward organizations into Medicare participation. That is structural validation, not a pilot signal.

Where Does the Margin Actually Live?

Value-based care does not reward adoption. It rewards proof. Organizations that deploy digital health technologies without tying them to measurable outcome loops, reimbursement codes, and FHIR-compliant data pipelines will find that the revenue case erodes faster than the technology improves.

The ones that get it right treat digital health technologies not as a product category but as the clinical evidence layer that makes their VBC contracts viable, their shared savings calculable, and their quality benchmarks defensible. That distinction is where the margin lives.